This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Odaka, M. Articles by Albelda, S. M. Search for Related Content PubMed PubMed Citation Articles by Odaka, M. Articles by Albelda, S. M.

Eradication of Intraperitoneal and Distant Tumor by Adenovirus-mediated Interferon-ß Gene Therapy Is Attributable to Induction of Systemic Immunity¹

Thoracic Oncology Research Laboratory, Division of Pulmonary, Allergy, and Critical Care Medicine [D. H. S., R. W., M. K., S. M. A.], Department of Surgery [M. O., K. M. A., L. R. K.], Institute for Human Gene Therapy [Y. Z., G-P. G., J. M. W.], University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, and Biogen, Inc., Cambridge, Massachusetts 02142 [J. B.]

Malignant mesothelioma remains an incurable disease for which immune-modulatory therapies, such as exogenous cytokines, have shown some promise. One such cytokine, IFN-ß, has potent antiproliferative and immunostimulatory activity in vitro, but its in vivo use has been limited by toxicity. We thus conducted studies evaluating intracavitary delivery of a replication-deficient adenoviral (Ad) vector encoding for the murine IFN-ß gene (Ad.muIFN-ß) in mouse models of malignant mesothelioma. In contrast to multiple injections of recombinant protein, a single i.p. injection of Ad.muIFN-ß into animals with established tumors elicited remarkable antitumor activity leading to long-term survival in >90% of animals bearing either AB12 or AC29 i.p. mesotheliomas. A control adenovirus vector had minimal antitumor effect in vivo. Significant therapeutic effects were also seen in animals treated with large tumor burdens. Importantly, treatment of i.p. tumor also led to reduction of growth in tumors established at a distant site (flank). A number of experiments suggested that these effects were attributable to an acquired CD8⁺ T-cell-mediated response including: (a) the induction of long-lasting antitumor immunity; (b) loss of efficacy of Ad.muIFN-ß in tumor-bearing, immune-deficient (SCID, SCID/beige) mice; (c) detection of high levels of specific antitumor cytolytic activity from unstimulated splenocytes harvested from Ad.muIFN-ß-treated animals that was abolished by CD8⁺ T-cell depletion; and (d) abrogation of antitumor effects of Ad.muIFN-ß in tumor-bearing CD8⁺ T-cell-depleted animals. These data show that intracavitary IFN-ß gene therapy using an adenoviral vector provides strong CD8⁺ T-cell-mediated antitumor effects in murine models of mesothelioma and suggest that this may be a promising strategy for the treatment of localized tumors such as mesothelioma or ovarian cancer in humans.

This article has been cited by other articles:

				C. L. Willmon, V. Saloura, Z. G. Fridlender, P. Wongthida, R. M. Diaz, J. Thompson, T. Kottke, M. Federspiel, G. Barber, S. M. Albelda, et al. Expression of IFN-{beta} Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of Mesothelioma Cancer Res., October 1, 2009; 69(19): 7713 - 7720. [Abstract] [Full Text] [PDF]

				J. H. Maxeiner, R. Karwot, K. Sauer, P. Scholtes, I. Boross, M. Koslowski, O. Tureci, R. Wiewrodt, M. F. Neurath, H. A. Lehr, et al. A Key Regulatory Role of the Transcription Factor NFATc2 in Bronchial Adenocarcinoma via CD8+ T Lymphocytes Cancer Res., April 1, 2009; 69(7): 3069 - 3076. [Abstract] [Full Text] [PDF]

				S. Kim, G. Buchlis, Z. G. Fridlender, J. Sun, V. Kapoor, G. Cheng, A. Haas, H. K. Cheung, X. Zhang, M. Corbley, et al. Systemic Blockade of Transforming Growth Factor-{beta} Signaling Augments the Efficacy of Immunogene Therapy Cancer Res., December 15, 2008; 68(24): 10247 - 10256. [Abstract] [Full Text] [PDF]

				D. H. Sterman, A. Recio, R. G. Carroll, C. T. Gillespie, A. Haas, A. Vachani, V. Kapoor, J. Sun, R. Hodinka, J. L. Brown, et al. A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses Clin. Cancer Res., August 1, 2007; 13(15): 4456 - 4466. [Abstract] [Full Text] [PDF]

				R. J. May, T. Dao, J. Pinilla-Ibarz, T. Korontsvit, V. Zakhaleva, R. H. Zhang, P. Maslak, and D. A. Scheinberg Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells Clin. Cancer Res., August 1, 2007; 13(15): 4547 - 4555. [Abstract] [Full Text] [PDF]

				E. Suzuki, S. Kim, H.-K. Cheung, M. J. Corbley, X. Zhang, L. Sun, F. Shan, J. Singh, W.-C. Lee, S. M. Albelda, et al. A Novel Small-Molecule Inhibitor of Transforming Growth Factor {beta} Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection Cancer Res., March 1, 2007; 67(5): 2351 - 2359. [Abstract] [Full Text] [PDF]

				D. H. Sterman, A. Recio, A. Vachani, J. Sun, L. Cheung, P. DeLong, K. M. Amin, L. A. Litzky, J. M. Wilson, L. R. Kaiser, et al. Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy Clin. Cancer Res., October 15, 2005; 11(20): 7444 - 7453. [Abstract] [Full Text] [PDF]

				M. J. Wilderman, J. Sun, A. S. Jassar, V. Kapoor, M. Khan, A. Vachani, E. Suzuki, P. A. Kinniry, D. H. Sterman, L. R. Kaiser, et al. Intrapulmonary IFN-{beta} Gene Therapy Using an Adenoviral Vector Is Highly Effective in a Murine Orthotopic Model of Bronchogenic Adenocarcinoma of the Lung Cancer Res., September 15, 2005; 65(18): 8379 - 8387. [Abstract] [Full Text] [PDF]

				E. Suzuki, V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity Clin. Cancer Res., September 15, 2005; 11(18): 6713 - 6721. [Abstract] [Full Text] [PDF]

				E. Suzuki, V. Kapoor, H.-K. Cheung, L. E. Ling, P. A. DeLong, L. R. Kaiser, and S. M. Albelda Soluble Type II Transforming Growth Factor-{beta} Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity Clin. Cancer Res., September 1, 2004; 10(17): 5907 - 5918. [Abstract] [Full Text] [PDF]

				R. J. Kruklitis, S. Singhal, P. Delong, V. Kapoor, D. H. Sterman, L. R. Kaiser, and S. M. Albelda Immuno-gene therapy with interferon-{beta} before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 123 - 130. [Abstract] [Full Text] [PDF]

				P. DeLong, T. Tanaka, R. Kruklitis, A. C. Henry, V. Kapoor, L. R. Kaiser, D. H. Sterman, and S. M. Albelda Use of Cyclooxygenase-2 Inhibition to Enhance the Efficacy of Immunotherapy Cancer Res., November 15, 2003; 63(22): 7845 - 7852. [Abstract] [Full Text] [PDF]

				C. Jackaman, C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. S. Robinson, and D. J. Nelson IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2 J. Immunol., November 15, 2003; 171(10): 5051 - 5063. [Abstract] [Full Text] [PDF]

				M. Obuchi, M. Fernandez, and G. N. Barber Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity J. Virol., August 15, 2003; 77(16): 8843 - 8856. [Abstract] [Full Text] [PDF]

				H. Alizadeh, K. Howard, J. Mellon, E. Mayhew, D. Rusciano, and J. Y. Niederkorn Reduction of Liver Metastasis of Intraocular Melanoma by Interferon-{beta} Gene Transfer Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 3042 - 3051. [Abstract] [Full Text] [PDF]

				H. Nakanishi, Y. Mizutani, A. Kawauchi, O. Ukimura, T. Shiraishi, M. Hatano, M. Mizuno, J. Yoshida, and T. Miki Significant Antitumoral Activity of Cationic Multilamellar Liposomes Containing Human IFN-{beta} Gene against Human Renal Cell Carcinoma Clin. Cancer Res., March 1, 2003; 9(3): 1129 - 1135. [Abstract] [Full Text] [PDF]